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Abstract
Introduction Environmental enteric dysfunction (EED) is
a subacute inflammatory condition of the small intestinal
mucosa with unclear aetiology that may account for
more than 40% of all cases of stunting. Currently, there
are no universally accepted protocols for the diagnosis,
treatment and ultimately prevention of EED. The
Bangladesh Environmental Enteric Dysfunction (BEED)
study is designed to validate non-invasive biomarkers
of EED with small intestinal biopsy, better understand
disease pathogenesis and identify potential therapeutic
targets for interventions designed to control EED and
stunting.
Methods and analysis The BEED study is a communitybased intervention where participants are recruited from
three cohorts: stunted children aged 12–18 months (length
for age Z-score (LAZ) <−2), at risk of stunting children
aged 12–18 months (LAZ <−1 to −2) and malnourished
adults aged 18–45 years (body mass index <18.5 kg/
m2). After screening, participants eligible for study
provide faecal, urine and plasma specimens to quantify
the levels of candidate EED biomarkers before and after
receiving a nutritional intervention. Participants who fail
to respond to nutritional therapy are considered as the
candidates for upper gastrointestinal endoscopy with
biopsy. Histopathological scoring for EED will be performed
on biopsies obtained from several locations within the
proximal small intestine. Candidate EED biomarkers
will be correlated with nutritional status, the results
of histochemical and immunohistochemical analyses
of epithelial and lamina propria cell populations, plus
assessments of microbial community structure.
Ethics and dissemination Ethics approval was
obtained in all participating institutes. Results of this
study will be submitted for publication in peer-reviewed
journals.
Trial registration number ClinicalTrials.gov ID:
NCT02812615. Registered on 21 June 2016.

Strengths and limitations of this study
►► This study will compare a wide array of non-

invasive biomarkers of environmental enteric
dysfunction (EED) to the diagnostic gold standard:
intestinal histopathology.
►► A histological scoring system will be developed for
identifying EED and describing its severity.
►► This study will be one of the largest communitybased nutritional interventional studies in improving
the growth parameters in children with stunting.
►► Due to ethical reasons, collecting small intestinal
tissue from healthy population of the same
community will not be possible.
►► ‘Failure to thrive’ criterion was selected based on
assumptions as no data were available.

Introduction
Environmental enteric dysfunction (EED),
previously known as tropical enteropathy
and environmental enteropathy, is a subacute
inflammatory condition of the small intestinal mucosa with unclear aetiology. EED
has been associated with a variety of environmental exposures and host factors and
is implicated in growth faltering.1 Linear
growth faltering typically occurs within the
first 2 years of life and after this period, it is
difficult to reverse.2 Globally, there are more
than 160 million stunted children (length for
age Z-score (LAZ) <−2).3 Previous work in
Gambia has revealed that 43% of observed
growth faltering was associated with evidence
of small intestinal enteropathy.4 There are
no universally accepted protocols for the
diagnosis and treatment of EED. The main
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impediments are a paucity of validated non-invasive
biomarkers of small intestinal health, a lack of understanding of the pathologic state of the small intestine in
EED and rudimentary knowledge of disease mechanisms.5
While there are several candidate surrogate biomarkers
of EED, to our knowledge none of these non-invasive
biomarkers have been directly correlated with the diagnostic gold standard: intestinal histopathology. The
Bangladesh Environmental Enteric Dysfunction (BEED)
study, a community-based intervention study, is designed
to validate candidate non-invasive biomarkers of EED and
to identify potential therapeutic targets for interventions.
This report describes the BEED study design, including
the biospecimens and data types that are being collected
for analyses.
Methods and analysis
The protocol for the BEED study (
ClinicalTrials.
gov
identifier NCT02812615) was developed through a
collaborative effort among International Centre for
Diarrhoeal Disease Research, Bangladesh (icddr,b),
Dhaka Medical College and Hospital (DMCH), Bangabandhu Sheikh Mujib Medical University (BSMMU),
Dhaka, Dhaka Shishu Hospital, Dhaka, Apollo Hospitals, Dhaka, Bangladesh, University of Virginia, USA
and Washington University, USA. The study is funded by
the Bill and Melinda Gates Foundation under its Global
Health Program (http://www.gatesfoundation.org/How-
We-Work/Quick-Links/Grants-Database/Grants/2015/

Figure 1

2

11/OPP1136751). Enrolment has been initiated and is
expected to continue until December 2018.
Objectives
The goals of this study are to (1) develop a histological
scoring system for identifying EED and describing its
severity; (2) employ this scoring system to test the validity
of proposed, candidate non-invasive biomarkers of EED
and identify novel biomarkers; (3) test the degree of
correlation between EED score and nutritional status
defined by anthropometry; (4) determine the role of
the gut microbiota in the pathogenesis of EED, in part
through transplantation of luminal/mucosal proximal
small intestinal and faecal microbiota from malnourished children with and without histopathological
evidence of EED into gnotobiotic mice to directly
test transmissibility of gut barrier/mucosal immune,
growth and metabolic phenotypes and (5) characterise
biological pathways that operate in the host and/or
gut microbiota that are associated with EED to identify
potential therapeutic targets.
Study settings and participants
The overall design of the BEED study is illustrated in
figure 1. There is a community-based nutrition intervention group and a comparison group. In the nutrition
intervention group, participants are being recruited
from two age groups: a child cohort (age 12–18 months)
and an adult cohort (age 18–45 years). The child cohort
consists of individuals who are stunted (LAZ <−2) and

Study design of Bangladesh Environmental Enteric Dysfunction study. GI, gastrointestinal.
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Table 1 Nutrition and health interventions
Intervention

Delivery method

Egg

One egg daily, 6 days a week for either
2 months (children at risk for stunting and
malnourished adults) or 3 months (stunted
children)
150 mL whole milk daily, 6 days a week for
either 2 months (children at risk for stunting
and malnourished adults) or 3 months
(stunted children)

Milk

Micronutrient
sprinkles

–Parents will be given one sachet of
multiple micronutrient sprinkles per day to
be administered to the child at home with
the midday meal for 2 months
–Each sachet contains one recommended
dietary allowance (RDA) of vitamin A,
vitamin C, folic acid, iron and zinc

Nutritional
counselling

Parents/caregivers will be provided with
nutritional counselling with particular
emphasis on adding vegetable oil to the
cooked diet as a source of energy as well
as sources of animal-based products, such
as small fish or chicken meat, and so on
along with regular intake of vegetables

Antihelminthic
treatment

Treatment

–As per national guidelines
–If participants have not been treated for
helminths in the preceding 3 months, will
get either 200 mg of albendazole or 10 mg/
kg pyrantel pamoate single dose
Intercurrent illnesses

those who are at risk of stunting (LAZ <−1 to −2). These
two subgroups will be used to compare histopathological features of EED with LAZ scores. The adult cohort
consists of malnourished individuals (body mass index
(BMI) <18.5 kg/m2) who will provide an opportunity to
further explore the association between body mass (in
this case low BMI) and the pathological features of EED
and also critically assess the degree to which histopathological features of EED in children manifest in adults.
The BEED study is recruiting two control groups
in order to compare the histological features in their
duodenal mucosal biopsies with those of documented
in cases of EED. Due to obvious ethical considerations,
it is not possible to collect small intestinal biopsy samples
from entirely healthy and asymptomatic subjects. Therefore, biopsies are being collected from children who
are neither stunted nor suffering from EED and who
undergo upper gastrointestinal (UGI) endoscopy as part
of their clinical care. This control group of children are
being recruited by the collaborators at the University of
Virginia Hospital in Charlottesville, Virginia, USA. An
equal number of age-matched and sex-matched healthy
adult controls (BMI >18.5) suffering from functional
dyspepsia who have no evidence of any organic diseases
are being recruited from the Gastroenterology Outpatient
Mahfuz M, et al. BMJ Open 2017;7:e017768. doi:10.1136/bmjopen-2017-017768

Department of DMCH and the icddr,b Staff Clinic and
undergo UGI endoscopy.
Following application of the inclusion/exclusion
criteria listed in online supplementary file 1, undernourished children and adults are receiving nutrition and
health interventions (table 1). Participants who fail to
respond to nutritional therapy are considered eligible
for UGI endoscopy with mucosal biopsies. Candidate
EED biomarkers are being measured in faeces, urine and
plasma samples collected from participants once before
and once after the nutritional intervention.
The BEED study is conducted among residents of
Mirpur, one of the 21 administrative units of the nation’s
capital, Dhaka. The Mirpur area is located 7–8 km from
the icddr,b Dhaka Hospital at Mohakhali. Mirpur has
a population of ~500 000 living in an area of 14.22 km2:
that is, the population density is more than 38 000 people
per square kilometre. The detailed socioeconomic and
demographic information of the study location has been
published elsewhere.6
Sample size
Participants are being recruited in a cross-sectional
manner. Sample size calculations were predicted on
the following assumptions: prevalence of stunting at
our study site is 40%; after receiving nutrition intervention ~20% will fail to manifest improved linear growth;
only one-third will give their consent for endoscopy
and 90% of the stunted children will have one or more
abnormal gut biomarkers with a precision of 10% and
95% CI. Using the formula n=(Z1−α/2)2×P×(1−P)/d2,
where n is the required sample size without attrition; P is
the prevalence of one or more abnormal gut biomarker in
stunted children=90% or 0.9; d is the level of actual precision=10% or 0.1; Z1−α/2 is the value for standard normal
distribution at 95% level of significance=1.96, a minimum
of 35 stunted children, 35 children at risk of stunting and
35 malnourished adults will be needed for UGI endoscopy and biopsy. Therefore, the final sample size for
endoscopy is 105 subjects (35+35+35). As endoscopy is
an invasive procedure, we assume that only one-third of
those who will fail to respond after nutrition intervention
will give consent for the procedure. As a consequence,
the ‘basic’ sample size was increased threefold for a
minimum of 105 (35×3) stunted children, 105 (35×3)
children at risk of stunting and 105 (35×3) malnourished
adults. To achieve this goal, 525 stunted children, 525
children at risk of stunting and 525 malnourished adults
will be recruited for nutrition interventions, based on the
assumption that ~20% of each group will fail to respond
despite the nutritional intervention. To enrol the desired
numbers of participants, at least 3977 (1312+2665) children 12–18 months old and 2100 adults needed to be
surveyed based on the current prevalence of malnutrition in both the age groups. An equal number (35) of
age-matched and sex-matched apparently healthy adult
controls (BMI >18.5) will be recruited from the outpatient department of DMCH and icddr,b Staff Clinic. Apart
3
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from the dyspeptic symptoms by Rome III criteria,7 these
subjects will have no other symptoms.
Dietary supplementation
Supplementation (table 1) of the usual home diet with
one boiled egg and 150 mL of whole milk provide an
additional 745 kilojoules, 11.1 g of protein and 11.5 g
of fat to the daily diet of enrolled subjects. The duration
of the intervention is 3 months for the stunted cohort
and 2 months for those who are at risk for stunting and
malnourished adults. Egg and milk were selected considering the nutritional values and the fact that they have
shown acceptable to the target population in a small pilot
study. Multiple studies have found significant positive
effects of egg and milk on linear growth.8–10
Nutritional therapy is delivered between the morning
and midday meal, anytime between 10:00 am to 11:30 am
to avoid the food substitution. Participants are asked to
come to the designated nutrition centre daily for their
nutritional therapy in order to avoid the issue of food
sharing with other family members. A staff member visits
the family’s household if a participant defaults in coming
to the nutrition centre. Study co-investigators also visit
nutrition centres regularly to monitor food left over,
absenteeism and other issues of compliance.
We assume that this regimen of food supplementation
plus counselling will result in incremental improvement
in linear growth of participant children. A participant is
discontinued from the study and referred for medical
evaluation if he/she shows reluctance to feed for 7
consecutive days, which includes daily intake of ≤50% of
the offered food.
Collection, preparation and archiving of biological samples
All biological samples (blood, urine, stool, breath,
duodenal aspirates and endoscopic biopsies) are
collected, prepared and preserved (see online supplementary file 2) as per the standard operating procedures
(SOPs) prepared for this protocol.
Breath samples are being collected for testing of small
intestinal bacterial overgrowth (SIBO). The first SIBO
test is performed before the nutrition intervention
and a second SIBO test is done 1–2 weeks prior to the
endoscopy, so that findings from the endoscopy can be
compared with results obtained from the hydrogen breath
tests. QuinTron Breath tracker machine and associated
QuinTron accessories are used for sample collection and
analysis.11
Faecal samples are collected and cryopreserved within
20 min of production. At the site of collection, samples
are aliquoted into sterile, prelabelled 2 mL cryophials
and immediately placed into precharged liquid nitrogen
dry cryo-shippers for transport back to the laboratory
where they are transferred into a −80°C freezer prior to
shipping. No additives, preservatives or media is added
to the faecal samples. Culture-independent as well as
culture-based analyses of the faecal microbiota (microbial community samples obtained from the UGI tract at
4

the time of endoscopy) will be performed at Washington
University in St. Louis, USA.
All other samples for biomarker assessment are carried
to the laboratory using cool box and cool packs. For
blood samples, with all aseptic precautions 5 mL venous
blood is collected in a blood collection tube (S-Monovette 7.5 mL, Sarstedt) and transported to laboratory.
Initially, 0.5 mL blood is transferred into a centrifuge tube
and the remaining 4.5 mL is centrifuged for the separation of plasma. The plasma is then aliquoted and stored
at −80°C. Chlorhexidine is added to urine samples as a
preservative. All the samples from each individual are
collected within a 3–4 days window period.
Biomarkers
A wide array of biomarkers of enteropathy will be tested
in the BEED study. A list of candidate biomarkers was
prepared after a thorough literature review and analysis of
data emanating from the Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the
Consequences for Child Health and Development (MALED)12–14 and Performance of Rotavirus and Oral Polio
Vaccines in Developing Countries (PROVIDE)15 studies
(table 2).
Indications for and details of the procedures used for UGI tract
endoscopy and mucosal biopsy
After completion of nutritional therapy, all enrolled
participants are assessed for responses. Definitions of
‘failure to thrive/respond’ are as follows:
►► LAZ score remains <−2 for members of the stunted
children cohort
►► LAZ score remains <−1 for the ‘at risk of stunting’
children cohort
►► BMI <18.5 kg/m2 and <10% increase in BMI for those
in the adult cohort
Participants who meet the study definition of ‘failure to
thrive/respond’ are further checked for the presence of
any secondary cause of malnutrition such as tuberculosis,
any parasitic infection, and so on. If nothing conclusive is
found, the participant may undergo preparations for UGI
endoscopy with biopsy. Participants with celiac disease
(as defined by tissue transglutaminase IgA, and clotting
disorders (determined by prothrombin time/International normalised ratio (INR) coagulopathy tests) will be
excluded from the study. There is no published information about the prevalence of celiac disease in Bangladesh
from any representative sample.16 One study of hospitalised adult patients with irritable bowel syndrome observed
that the prevalence of celiac disease was 9%.17 In the
BEED study, immediate test results for celiac disease are
not available; therefore, we are unable to screen out individuals with this disorder before nutrition intervention
is initiated. Nonetheless, BEED will screen 1575 participants for celiac disease; as such, it will be the first study
in Bangladesh to explore the prevalence of this disorder
in a paediatric population. Necessary management and
Mahfuz M, et al. BMJ Open 2017;7:e017768. doi:10.1136/bmjopen-2017-017768
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Table 2 Summary table for non-invasive biomarker candidates and related processes
Process of gut health

Biospecimen

Non-invasive biomarkers

Epithelial health and repair
Intestinal barrier dysfunction and
bacterial translocation

Faeces
Blood and urine

Reg1B
Alpha-1-antitrypsin, lactulose/rhamnose ratio

Intestinal inflammation

Faeces

Myeloperoxidase, neopterin, calprotectin

Systemic inflammation

Blood

sCD14, CRP, AGP, KT ratio

Epigenetic metabolomes

Blood

LRP1

Enteric infection

Faeces, breath sample

TaqMan Array Card, SIBO

Nutrient malabsorption
Celiac Disease screening

Blood
Blood

Ferritin, zinc, GLP-2, pepsinogen I/II ratio
IgA tissue transglutaminase, total IgA

AGP, alpha 1-glycoprotein; CRP, C reactive protein; KT ratio, kynurenine/tryptophan ratio; LRP1, low density lipoprotein receptor-related
protein 1; GLP-2, glucagon-like peptide-2; Reg1B, regenerating family member 1 beta proteins; sCD14, soluble cluster of differentiation 14;
SIBO, small intestinal bacterial overgrowth.

counselling is provided to the participants suffering from
celiac disease or clotting disorders.
Endoscopy of the UGI tract is performed as per standards recommended by North American Society for
Pediatric Gastroenterology, Hepatology and Nutrition,
the American College of Gastroenterology and the American Society for Gastrointestinal Endoscopy (ASGE).18
The procedure is generally scheduled in the early
morning after fasting from midnight. Gastroenterologists, who perform endoscopy, discuss with the subjects
and their guardians regarding the indication of the
procedure, the sedation plan, the risks associated with
sedation and describe the total procedure, likely benefits,
common adverse events (AEs), alternatives to the procedure and the prognosis of the subjects if endoscopy is
declined. After this discussion and proper counselling, the
gastroenterologists personally obtain consent from the
subjects on the day of the procedure. A separate consent
is obtained for sedation. A preprocedure assessment that
includes medical history and physical examination is also
completed by the gastroenterologist himself.
Once the preprocedure assessment is completed and
no concerns are identified by the gastroenterologist, the
subject is proceeded to the endoscopy room. A qualified anaesthetist attends the procedure to assess and
administer the steps, as required, for sedation. Before
sedation is administered, the intended level of sedation
is graded (nil, minimal, moderate and deep sedation
or general anaesthesia) as per the recent guidelines of
ASGE.18 19 Children are sedated using general anaesthesia
by an expert and qualified anaesthetist. UGI endoscopies
of adult participants are performed under conscious
sedation using midazolam. The oropharynx is anaesthetised with 10% lidocaine spray; concomitantly, midazolam
(3–5 mg) is injected intravenously to induce conscious
sedation.19
The endoscopic procedure is performed with a goal
of collecting up to six biopsies from each child and up
to eight biopsy samples from each adult participant. As
per the protocol, one biopsy is taken from the duodenal
Mahfuz M, et al. BMJ Open 2017;7:e017768. doi:10.1136/bmjopen-2017-017768

bulb; the rest of the biopsies are collected from the distal
part of the duodenum. Duodenal fluid is aspirated for
culture-independent and culture-based assessments of
the composition of the proximal small intestinal microbial community and for assays of host and microbial
products. Secretions are rapidly aspirated first from the
second portion of the duodenum using sterile Endoscopic Retrograde Cholangiopancreatography (ERCP)
catheters. Following this initial aspiration, the postbulbar
mucosa is irrigated with a maximum of 25 mL of sterile
0.9% normal saline, and the lumen contents are aspirated through the ERCP catheter. The lavaged aspirates
are aliquoted and processed as per the SOP described in
table 3.
Participant undergoing endoscopy is observed in the
postprocedure recovery room until he/she meets predetermined standard discharge criteria.20 The subjects who
undergo the endoscopy procedure are followed up for
14 days after the procedure to determine whether any
AEs have occurred after discharging from the endoscopy
unit and whether these are attributable to the procedure.
An appropriate course of action will be followed if such
events occur; the cost of management of all postprocedure complications will be borne by the study. Participants
receive appropriate treatment based on the results of
reports from the endoscopy and biopsy procedure. As
for example, participants diagnosed endoscopically with
antral gastritis are screened for Helicobacter pylori and
prescribed proper treatment, as per standard recommendations.
Protocol timeline
The overall schedule for enrolment, interventions and
assessments, including UGI endoscopy and biopsies, is
described in table 4.
Data collection, management and storage
Data collection tools for this study include case report
forms, laboratory worksheets and source documentation. Complete source documentation (study visits,
5
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Table 3 Biopsy specimen processing
Specimen

Recipient fluid

Processing

Purpose

Biopsy #1
Biopsy #2

RNAlater
HBSS

Nucleic acid extraction
FACS

Transcriptomics
Cell isolation

Biopsy #3

None

Flash frozen

Culture-independent and culture-based assays
of mucosa-associated microbial community

Biopsy #4

None

Flash frozen

Archiving for validation of drug targets

Biopsies #5 and #6*

Formalin

Paraffin embedded

Duodenal Aspirate

Microbiota: glycerol/
cysteine solution
Other: Nil

Precharged N2 dry
shipper to −80 freezer

Histochemistry (H&E) and
immunohistochemistry;
Morphometric analyses and EED scoring
Culture-independent and culture-based assays

*Biopsy site: biopsy #6 from duodenal bulb, all others distal to the ampulla of Vater.
EED, environmental enteric dysfunction; FACS, fluorescence-activated cell sorting; HBSS, Hank’s balanced salt solution.

laboratory reports, and so on) is done for each participant in individual study charts. All laboratory specimens,
reports, study data collection and administrative forms
are identified by coded number to maintain participant
confidentiality and to enable tracking throughout the
study. Bar-coded labels are used for all laboratory specimens. All information regarding study subjects are kept
in password-protected computer files, or in locked file
cabinets that can be accessed only by authorised study
personnel. Anthropometric data (table 4) are collected
twice in a month. The total amounts of food offered,
consumed and leftover are recorded. All foods are
weighed with precision scales (see online supplementary
file 3). Multiple food frequency data are collected from
all the participants, whereas a 24 hours dietary recall data
are being collected from a subgroup of randomly selected
children as well as adults (50 in each group) to assess their
food habits and food substitution, if any.
Data analysis plan
This study will yield a rich dataset containing socio-demographic and anthropometric information, food security
status, plus faecal, urine, plasma and breath associated
biomarkers, the results of histopathological measurements as well as data related to small intestinal gut
health risk factors. After evaluation of biopsy specimens,
a pathologist will assign a histopathological grade, in a
blinded fashion, based on histological changes deemed to
be signatures of EED: these include changes in mucosal
architecture (shortening of the villi, increase in the depth
of the crypts), changes in immune-inflammatory cell
content (lymphocytic infiltration into the lamina propria
and epithelium) and changes in epithelial features
(goblet cell content, evidence of enterocyte injury and so
on).21 Statistical tests of correlations between histopathological scores, biomarker levels and anthropometric
changes will be performed. An ‘inter-group’ comparison
(stunted children vs children at risk of stunting; stunted vs
non-stunted, and so on) will be performed for validation
of histopathological grading. The analysis plan includes
6

relatively simple linear modelling of all continuous and
dichotomous measures to establish whether biomarkers
are associated with anthropological changes or not.
Biomarkers exhibiting statistically significant changes will
be identified and their final validation will be performed
by comparing their levels with histopathological changes.
An important research question is whether enteric
infections, and gut immune responses to those infections,
are associated. While preliminary inferences of linkage
are possible from a careful interpretation of simple
univariate and bivariate analyses, instrumental variable
analysis (for the control of unmeasured covariates) will
also be performed.
Being an invasive procedure requiring hospitalisation,
histopathological diagnosis of EED will not be possible as
a routine approach in at-risk populations in low-income
settings. A goal of this project is to validate surrogate
biomarkers of the disease and use these for developing
models to predict future negative histopathological and
clinical outcomes. From a list of significant biomarker
variables, we will select a ‘best’ subset by using a branch
and bound algorithm. This method will test all biomarker
subsets in contrast to the more usual forward or reverse
stepwise regression. As development of prediction model
risks over-fitting to the data set, we plan to partition the
data set into model training (2/3) and test (1/3) subsets,
using the test set at the end of the fitting to establish an
unbiased estimate of the generalisation error. We will
estimate the prediction error in the training set using
cross-validation methods. A subset model of biomarkers
will also be used to create a composite score of EED.
Monitoring and quality control measures
We are using previously established and validated SOPs
for data collection, monitoring and quality control
measures.12 22 A field supervisor re-collects 10% of all
collected data, including anthropometry and dietary
assessments. Monitoring reports are prepared weekly.
An Excel-based program is used for scheduling data and
sample collection from each participant. All activities
Mahfuz M, et al. BMJ Open 2017;7:e017768. doi:10.1136/bmjopen-2017-017768

X
X
X
X

Enrolment
Pre-enrolment survey

Eligibility screen

Informed consent

Mahfuz M, et al. BMJ Open 2017;7:e017768. doi:10.1136/bmjopen-2017-017768

X
X
X
X
X
X
X

 Anthropometry*

 Blood biomarkers

 Stool biomarkers and TAC

 Microbiota

 Urine L:R

 Breath SIBO

 UGI endoscopy and biopsy
 Histopathology, IHC,
morphometry

X

Month 1 (T1)

X

Month 2 (T2)

X

Month 3 (T3)

X

X

X

X

X

X

X

X

Week 1 (T4)

X

Week 2 (T5)

Eligibility
Postintervention assessment for
assessment
UGI endoscopy

X

Week 3 (T6)

UGI endoscopy
and biopsy

*Anthropometry done fortnightly.
IHC, immunohistochemistry; L:R, lactulose/rhamnose; SIBO, small intestinal bacterial overgrowth; TAC, TaqMan Array Card; UGI, upper gastrointestinal; SES, socio-economic status; WASH,
water-sanitation-hygiene; FFQ, food frequency questionnaire.

X

0

Preintervention Nutrition intervention

 SES, WASH, FFQ

Assessments

 Malnourished adult

 Children at risk of stunting

 Stunted children

Interventions

−T1

Enrolment

Study period

Schedule of enrolment, interventions and assessments

Timepoint

Table 4
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of the BEED study are being performed according to
a Manual of Procedures (a collection of all SOPs). A
summary of quality control measures is described in
online supplementary file 4.

reported to the ERC of icddr,b within 24 hours of the
site’s awareness of the event. In the event that medical
care is required outside of the protocol, all necessary and
available treatments are provided, free of cost.

Challenges
Several questions arose in the development and implementation of the BEED study, all of which were brought
to the Investigators’ Committee for discussion and resolution. For example, AEs that may arise during endoscopy
were a big concern and to solve the issues, investigators
have developed a priori definitions, assessment criteria
and action guidelines. Morbidity and poor appetite also
represent a big challenge; by providing proper counselling and by practising supportive feeding techniques, this
issue can be resolved.

Safety issues for UGI endoscopy and biopsy
Although never without elements of risk during the
procedure and anaesthesia, endoscopy is a safe procedure
when conducted by trained experienced personnel in a
well-equipped facility. In Gambia, a study was done where
40 children were recruited and underwent endoscopy
under intravenous sedation.23 In the University Teaching
Hospital, Lusaka, Zambia, investigators collected duodenal
biopsy samples via endoscopy under sedation with midazolam from 41 malnourished children to compare their
inflammatory status with normal children.24 Neither of
these studies reported any endoscopy-related AEs during
or after the procedures. Following standard recommendations and guidelines, endoscopic procedures are
performed by members of a team of co-investigators
consisting of experienced consultant gastroenterologists from BSMMU, DMCH, Apollo Hospital, Dhaka and
icddr,b. A qualified anaesthetist attends the procedure
to assess and administer steps as required for sedation.
The participant’s oxygen saturation level, pulse rate and
blood pressure are continuously monitored throughout
the procedure. Resuscitation measures and complete ICU
support remain available during the procedure for immediate resuscitation if necessary. Clinical findings from the
biopsies (eg, presence of gastritis) are made available
quickly so that appropriate treatment can be undertaken
in a timely manner.

Ethics and dissemination
Ethical approvals
Ethical approvals were obtained from Research Review
Committee (RRC) and Ethical Review Committee (ERC)
of icddr,b (protocol no: PR-16007; Version 1.03; March 1,
2016), the Ethical Committee of Dhaka Medical College
(DMC/ ECC/2016/39). Institutional Review Board for
Health Sciences Research (IRB-HSR) of University of
Virginia, Charlottesville, the Human Research Protection
Office (HRPO) of Washington University in St. Louis (the
latter for analyses of collected biospecimens).
Consent
Each participant enrolled in BEED study is treated
according to what is morally right and proper. Separate
consent forms are being used for children and adult
participants. After complete disclosure, a signed informed
consent statement is obtained from each subject. For
minors, informed consent is obtained from the parents or
authorised legal guardian of the subject. The consenting
process takes place, preferably, in the residence of the
subject. If the subject or the parent(s)/guardian agree
to participate in the study, they sign the consent form or
provide an impression of their left thumb. The investigator and a witness also sign the form. For endoscopy, a
separate consent form is used and the aforementioned
procedure is followed. The consent form for endoscopy
clearly and fully describes, and demystifies, all aspects of
the process, including the risks related with the procedure. No information is remained withheld from the
participant.
Adverse events
Expected AEs for this protocol are those related to the
endoscopy/biopsy procedure that do not qualify as a
serious adverse event (SAE) and those associated with
phlebotomy and ingestion of lactulose/rhamnose solution. Both serious and non-SAEs are assessed for their
severity, their relationship to study participation and the
actions taken and their outcomes. All SAEs are being
8

Dissemination and publication
The data, results and other findings resulting from this
study will be published only after approval by a committee
consisting of the investigators of the protocol. The International Committee of Medical Journal Editors guidelines
will be used to establish authorship on papers.
Project status
As of May 2017, participant enrolment is ongoing.
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